Format

Send to

Choose Destination
Leuk Lymphoma. 2019 May;60(5):1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22.

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.

Author information

1
a Icahn School of Medicine at Mount Sinai , Tisch Cancer Institute , New York , NY , USA.
2
b Greenebaum Cancer Center , University of Maryland , Baltimore , MD , USA.
3
c Lombardi Comprehensive Cancer Center , Georgetown University Medical Center , Washinton , DC , USA.
4
d Abramson Cancer Center , University of Pennsylvania Perelman School of Medicine , Philadelphia , PA , USA.
5
e Department of Population Health , New York University , New York , NY , USA.
6
f New York Blood Center, Myeloproliferative Disorders Laboratory , New York , NY , USA.
7
g Section of Molecular Hematology, Department of Hematology/Oncology , University Medical Center Freiburg , Freiburg , Germany.
8
h Division of Biostatistics , Mayo Clinic Arizona , Scottsdale , AZ , USA.
PMID:
30668266
PMCID:
PMC6530779
[Available on 2020-05-01]
DOI:
10.1080/10428194.2018.1532509

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center